Miércoles 13 de mayo - 3:00 pm (EST) | Únase a MCN para una sesión de preguntas y respuestas sobre este tema con Chad Roy, PhD, y Ed Zuroweste, MD.

[link removed]
[link removed]
¿Es el COVID-19 areotransportado? Una sesión de preguntas y respuestas con Chad Roy, PhD y Ed Zuroweste, MD
Miércoles, 13 de mayo del 2020
12:00 PM (PST) | 3:00 PM (EST)
¡Disponible solo en inglés!
Regístrese aquí para el seminario ([link removed])
El virus detrás de la pandemia COVID-19 puede permanecer infeccioso en el aire durante más de 12 horas, según una investigación preliminar realizada en cuatro de los principales laboratorios de EE. UU. Los científicos involucrados en esta investigación advierten que la patogenicidad del COVID-19 en el aire puede haber sido subestimada por la Organización Mundial de la Salud. Todavía no está claro qué cantidad de virus SARS-CoV-2 necesitaría inhalar para enfermarse, pero los investigadores están descubriendo que es notablemente resistente en el aire cuando se pulveriza en partículas más pequeñas.

¿Qué significa esto para los médicos en primera línea? ¿Estos hallazgos cambian las recomendaciones que los médicos hacen a los pacientes? Únase a MCN para una sesión de preguntas y respuestas sobre este tema con Chad Roy, PhD, microbiólogo y Director de los programas de investigación de Enfermedades Infecciosas y Biodefensa en la Universidad de Tulane y Ed Zuroweste, MD, director médico fundador de MCN.

Presenters
Chad Roy, PhD
Dr. Roy is a microbiologist and director of the infectious disease aerobiology and biodefense research programs at Tulane University’s National Primate Center. He has focused his career on respiratory health and the aerobiology of airborne infectious diseases; specifically, on gaining a better understanding of aerosol infection in the context of the development and application of preclinical disease models; the majority of efforts are directed in the use of the nonhuman primate for this purpose. He is currently engaged in COVID-19 research, including serving as principal investigator of a $10.3 million National Institutes of Health grant to evaluate the nation's most promising vaccines and treatments to combat the disease.
Ed Zuroweste, MD
Dr. Zuroweste has over 30 years of experience as a family physician focused on the care of underserved populations in the US. For 20 years, Dr. Zuroweste maintained a full-time clinical practice in Chambersburg, Pennsylvania, first in private practice and later as the Medical Director of a Migrant/ Community Health Center. Dr. Zuroweste is the Founding Medical Director of the Migrant Clinicians Network. He is the Tuberculosis Medical Consultant for the Pennsylvania Department of Health. He is an Adjunct Assistant Professor of Medicine at Johns Hopkins School of Medicine for an international health elective for medical students in Honduras. Dr. Zuroweste served as a special medical consultant for the Global Influenza Program of the World Health Organization to help limited resource hospitals and clinics address the H1N1 pandemic and was part of the WHO Ebola Response Team in Guinea and Sierra Leone where he trained physicians and nurses to prepare to work in Ebola treatment centers.
Conéctate con nosotros
[link removed]
[link removed]
[link removed]
[link removed]
[link removed]
[link removed]
[link removed]
Having trouble? View this email in your browser ([link removed])

============================================================
Copyright © 2020 Migrant Clinicians Network, All rights reserved.
You are receiving this email because you signed up for the MCN mailing list.

Our mailing address is:
Migrant Clinicians Network
P.O. Box 164285
Austin, TX 78716
USA
** unsubscribe from this list ([link removed])
** update subscription preferences ([link removed])